IGF1R and Ewing sarcoma: Taken together, though notable RECIST responses were observed in 10–14% of the ES patients treated with single-agent IGF-1R-targeted therapies, the most likely development path that remains is one that capitalizes upon highly synergistic, rationally selected drug combinations that maximally ablate the entire signaling cascade upstream and downstream of mTOR.